<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645824</url>
  </required_header>
  <id_info>
    <org_study_id>HO134</org_study_id>
    <secondary_id>2015-000195-98</secondary_id>
    <nct_id>NCT03645824</nct_id>
  </id_info>
  <brief_title>Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)</brief_title>
  <acronym>HOVON134MF</acronym>
  <official_title>A Phase II Trial in Patients With Myelofibrosis (Primary, Post-ET or Post PV-MF) Treated With the Selective JAK2 Inhibitor Pacritinib Before Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stichting Hemato-Oncologie voor Volwassenen Nederland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stichting Hemato-Oncologie voor Volwassenen Nederland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell&#xD;
      transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of&#xD;
      MF patients, decreases spleen size and might diminish graft-versus-host disease (GvHD),&#xD;
      thereby improving the outcome of SCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite recent new therapeutic options, allogeneic Stem Cell Transplantation remains the only&#xD;
      curative option in patients with Myelofibrosis. Therefore, optimalization of this therapy&#xD;
      remains a major challenge. Improvement of the clinical condition of these patients,&#xD;
      decreasing spleen size can be accomplished by JAK2 inhibitor treatment and might improve SCT&#xD;
      outcome. In addition, selective JAK2 inhibitors might modulate GvHD which can also add to&#xD;
      improved SCT outcome. Also, decreasing the burden/activity of the disease before allo-SCT&#xD;
      might also improve final disease response. The first, limited, clinical data of ruxolitinib&#xD;
      treatment before allo-SCT show controversial effects on the outcome of SCT. Therefore,&#xD;
      additional prospective clinical trials have to be done to establish the role of JAK2&#xD;
      inhibition before allogeneic SCT. Since ruxolitinib has considerable myelosuppressive effects&#xD;
      which might limit the clinical use in some MF patients, other selective JAK2 inhibitors might&#xD;
      be useful in this setting. Pacritinib, as a JAK2/FLT3 inhibitor, has a very potent JAK2&#xD;
      inhibitory activity without myelosuppressive effects and might therefore be more suitable&#xD;
      than ruxolitinib. The major possible side effects are gastro-intestinal and can be managed&#xD;
      with medication. In several studies, pacritinib has shown to be effective in decreasing&#xD;
      spleen size and has shown to improve clinical condition of patients. Therefore, this compound&#xD;
      seems promising in improving the outcome of allo-SCT. Although pacritinib causes no&#xD;
      inhibition of JAK1 activity and therefore might have limited effects in decreasing&#xD;
      inflammatory response, this might also be of benefit since a &quot;withdrawal syndrome&quot; as has&#xD;
      been described after cessation of ruxolitinib is not to be expected.&#xD;
&#xD;
      With this trial, using pacritinib treatment before allo-SCT, the issue of improvement of SCT&#xD;
      outcome will be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients receiving allo-SCT, with failure within or at day 180 post-transplant.</measure>
    <time_frame>2 years</time_frame>
    <description>Failure can be defined by one of the following parameters:&#xD;
Primary graft failure&#xD;
Acute graft versus host disease grade 3-4&#xD;
Secondary graft failure&#xD;
Death, from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Adverse events will be monitored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Progression free survival as time between registration or SCT until progression/relapse or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Over all survival, calculated from either registration or SCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Death due to the disease or after progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Death not due to disease or relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life during and after treatment</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life during and after treatment will be recorded by use of the MPN-SAF questionnaire.&#xD;
From a total of 27 questions, the scores (from 0 to 10) from the following 10 questions are added and subsequently averaged to come to a total quality of life score.&#xD;
fatigue&#xD;
satisfction after a meal&#xD;
stomach complaints&#xD;
not able to perform activities&#xD;
concentration problems&#xD;
night sweat&#xD;
itch&#xD;
bone pain&#xD;
fever&#xD;
sudden weight loss</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Pacritinib treatment befor allo-SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pacritinib</intervention_name>
    <description>Patients receive up to 4 cycles of pacritinib before allo-SCT</description>
    <arm_group_label>Pacritinib treatment befor allo-SCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a confirmed diagnosis of post-ET, post-PV or primary myelofibrosis&#xD;
&#xD;
          -  Intermediate-2 or high-risk according to DIPSS plus (Appendix E)&#xD;
&#xD;
          -  Age 18-70 years inclusive&#xD;
&#xD;
          -  WHO performance status 0-2 (Appendix C)&#xD;
&#xD;
          -  All men and women of childbearing potential must agree to use adequate contraception&#xD;
             during the study&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Patient is capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with JAK2 inhibitors within 2 weeks of study inclusion. Patients&#xD;
             who have been treated with pacritinib as their previous JAK2 inhibitor treatment&#xD;
             cannot participate in this study&#xD;
&#xD;
          -  Any GI or metabolic condition (e.g. inflammatory or chronic functional bowel disorder&#xD;
             such as Crohn's Disease, Inflammatory Bowel Disease, chronic diarrhea or constipation)&#xD;
             that could interfere with absorption of oral medication&#xD;
&#xD;
          -  Left ventricular cardiac ejection fraction of ≤ 45% by echocardiogram or multigated&#xD;
             acquisition (MUGA) scan&#xD;
&#xD;
          -  Impaired liver and renal function, defined by liver transaminases (aspartate&#xD;
             aminotransferase [AST]/serum glutamic oxaloacetic transaminase [SGOT] and alanine&#xD;
             aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]), &gt;3 × the upper&#xD;
             limit of normal (ULN) (AST/ALT &gt;5 × ULN if transaminase elevation is related to MF),&#xD;
             direct bilirubin &gt;4× ULN, and creatinine clearance ˂ 40 ml/min.&#xD;
&#xD;
          -  Impaired coagulation function, defined by prothrombin time (PT)/international&#xD;
             normalized ratio (INR), partial thromboplastin time (APTT)&gt;1.5 x ULN.&#xD;
&#xD;
          -  Experimental treatment within four weeks before inclusion for PMF, Post-PV, or Post-ET&#xD;
             MF&#xD;
&#xD;
          -  Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D)&#xD;
&#xD;
          -  Treatment with a potent strong CYP3A4 inhibitor or a strong cytochrome P450 (CYP450)&#xD;
             inducer within the last 2 weeks&#xD;
&#xD;
          -  Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of&#xD;
             ≤100 mg per day, within the last 2 weeks&#xD;
&#xD;
          -  New York Heart Association Class II, III, or IV congestive heart failure&#xD;
&#xD;
          -  QTc prolongation &gt;450 ms as assessed by ECG and corrected by Federicia method or other&#xD;
             factors that increase the risk for QT interval prolongation (e.g., heart failure,&#xD;
             hypokalemia [defined as serum potassium &lt;3.0 mEq/L that is persistent and refractory&#xD;
             to correction], family history of long QT interval syndrome, or concomitant use of&#xD;
             medications that may prolong QT interval)&#xD;
&#xD;
          -  Significant recent bleeding history defined as NCI CTCAE grade ≥2 within the last 3&#xD;
             months, unless precipitated by an inciting event (e.g., surgery, trauma, injury)&#xD;
&#xD;
          -  Any history of CTCAE grade ≥2 non-dysrhythmia cardiac conditions within the last 6&#xD;
             months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions may be&#xD;
             considered for inclusion, with the approval of the principal investigator, if stable&#xD;
             and unlikely to affect patient safety.&#xD;
&#xD;
          -  Any history of CTCAE grade ≥2 cardiac dysrhythmias within the last 6 months. Patients&#xD;
             with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with&#xD;
             the approval of the principal investigator, if the dysrhythmias are stable,&#xD;
             asymptomatic, and unlikely to affect patient safety.&#xD;
&#xD;
          -  Patients with active, uncontrolled infections&#xD;
&#xD;
          -  Patients known to be HIV (human immunodeficiency virus)-positive&#xD;
&#xD;
          -  Active hepatitis A, B or C&#xD;
&#xD;
          -  History of active malignancy during the past 3 years, except basal carcinoma of the&#xD;
             skin or stage 0 cervical carcinoma&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes,&#xD;
             infection, hypertension, cancer, etc.)&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Any psychological, familial, sociological and geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter AW te Boekhorst, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter AW te Boekhorst, M.D. PhD</last_name>
    <phone>+31 10 703</phone>
    <phone_ext>4911</phone_ext>
    <email>p.teboekhorst@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>BE-Antwerpen-ZNASTUIVENBERG</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>BE-Gent-UZGENT</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>BE-Leuven-UZLEUVEN</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>BE-Roeselare-AZDELTA</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Amsterdam-AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Amsterdam-VUMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Groningen-UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>G. Huls</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NL-Maastricht-MUMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Nijmegen-RADBOUDUMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Rotterdam-EMCDANIEL</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Rotterdam-ERASMUSMC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Utrecht-UMCUTRECHT</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.hovon.nl</url>
    <description>HOVON Foundation (STICHTING HEMATO-ONCOLOGIE VOOR VOLWASSENEN NEDERLAND)</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemato-Oncology</keyword>
  <keyword>Allogeneic Stem Cell Transplantation</keyword>
  <keyword>Pacritinib</keyword>
  <keyword>JAK2 inhibitor</keyword>
  <keyword>Myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

